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Summary
BACKGROUND: After a steady decline for 20 years, the pace of decline of TB incidence in the 
United States has slowed.
METHODS: Trends in TB incidence rates and case counts since 1993 were analyzed using 
national US surveillance data. Patient characteristics reported during 2014–2017 were compared 
with those for 2010–2013.
RESULTS: TB rates and case counts have slowed to an annual decline 2.2% (95% confidence 
interval (CI): –3.4– –1.0) and 1.5% (95% CI: –2.7– –0.3) respectively, since 2012, with declines 
among US-born persons and no change among non-US–born persons. Overall, persons with TB 
diagnosed during 2014–2017 were older, more likely to have combined pulmonary and 
extrapulmonary disease compared with exclusively extrapulmonary disease, more likely to be of 
nonwhite race, and less likely to be human immunodeficiency virus-positive, or have cavitary 
pulmonary disease. During 2014–2017, non-US–born persons with TB were more likely to have 
diabetes while the US-born were more likely to have smear positive TB and use noninjecting 
drugs.
CONCLUSION: Changes in epidemiologic trends are likely to affect TB incidence for coming 
decades. CDC has called for increased attention toward preventing TB through detection and 
treatment of latent TB infection.
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Introduction
Since the early 1990s, cases of reported tuberculosis (TB) in the United States have declined 
from 26 673 in 1992, to 9105 in 2017.1 The decline is attributable in large part to improved 
TB case management, more consistent use of directly observed therapy, and widespread 
implementation of drug susceptibility testing.2,3,4 During 1995–2014, up to 319 000 cases 
were averted by improved TB control funding and management practices in the United 
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States.5 However, after 20 years of steady decline, the United States has experienced a 
slowing in progress toward TB elimination1,6 Annual TB incidence in the United States 
declined steadily from 9.7/100,000 persons during 1993 to approximately 3.0/100,000 
during 2013–2017 (range 3.0 to 2.8/100,000 during 2013–2017). As US TB incidence has 
declined, the proportion of TB patients in the United States who were born in high TB 
burden countries has shifted.1 We analyzed epidemiologic changes associated with the 
slowing of the pace of decline during 2014–2017.
Methods
Study population
We conducted the analysis by using the US National Tuberculosis Surveillance System 
(NTSS) data for as of June 1, 2018, for data regarding verified cases of TB reported from the 
50 states and the District of Columbia. A standardized report form, the Report of Verified 
Case of TB,7 with standard variable definitions has been used since 1993 to collect patient-
level data related to demographics, clinical characteristics, laboratory results, and social risk 
factors within the previous year before TB diagnosis. Additional variables (e.g., diabetes, 
immunosuppression not caused by human immunodeficiency virus [HIV] infection, end-
stage renal disease, and interferon-gamma release assay or nucleic acid amplification test 
results for diagnosis) were added in 2009 and have been collected by all TB program areas 
since 2010.7 Persons with TB are considered US-born if they are born in the United States, a 
US territory (Puerto Rico, Guam, US Virgin Islands, American Samoa, or the 
Commonwealth of the Northern Mariana Islands), or abroad of a US-citizen parent.
Analyses
Incidence rates of TB by racial/ethnic and nativity subcategories were calculated by using 
population denominator data from the American Community Survey.8 To assess changes in 
time trends that were significant by Monte Carlo permutation test at the P <.05 level, we 
used Joinpoint regression version 4.0.4 (National Institutes of Health, National Cancer 
Institute),9,10 using the default number of joinpoints of four to examine average annual 
percentage change (APC) for TB incidence rates and case counts overall and by origin of 
birth (nativity). An APC that is not significant indicates a flat slope or no significant change 
over time, i.e. the APC is not significantly different from a slope of zero. To determine if 
increased TB transmission might account for increases in TB cases, we examined the 
percentage of TB cases attributed to recent TB transmission on the basis of an algorithm that 
uses genotyping and epidemiologic information for plausible source cases over the previous 
2 years.11 Recent transmission analyses based on genotyping results were first applied 
nationwide in 2011; therefore, results for recent transmission are described for 2011–2017. 
We compared the frequency and proportion of TB patient demographic, diagnostic, and 
clinical characteristics for 2014–2017 with 2010–2013 to assess recent changes in the 
epidemiology of TB; 2010 was the starting point for that analysis to capture new NTSS 
variables adapted by all reporting areas that year and 2014 was chosen as the starting year 
for the comparison group because that was the first year after the joinpoint signifying the 
slowing of decline in incidence for both the US-born and the non-US–born. The binary 
outcome in multivariable models estimating relative risk for a TB patient having a certain 
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characteristic was the patient being reported in 2014–2017, compared with 2010–2013. 
SAS® version 9.4 (SAS Institute, Inc., Cary, North Carolina) was used for all bivariate and 
multivariable analyses, with P <.01 considered statistically significant. Multivariable models 
stratified by nativity were selected through backward elimination.
Institutional Review Board review was not required for this analysis, which used routinely 
reported de-identified national surveillance data. NTSS operates under an Assurance of 




During 1993–2017, a total of 369 300 confirmed TB cases were reported in the United 
States. The 1993 incidence was 9.7/100 000 and declined by varying degrees throughout the 
years (Figure 1a). During 2012–2017, incidence declined more slowly from 3.2/100,000 
persons in 2012 to 2.8/100,000 persons in 2017 (–2.2% APC; 95% CI: –3.4%– –1.0%). TB 
case counts followed a similar trend, with the exception of a rise in case count in 2015, but 
the overall trend was a statistically significant slight decline from 2012 to 2017, (–1.5% 
APC, 95% CI: –2.7– –0.3) (Figure 1b). When analyzing case counts for 24 states reporting 
at least 100 cases in 2017, there was no discernable geographic pattern of states with 
increasing or decreasing counts since 2015 or 2016.
Among non-US–born persons with TB (total 182 429 cases), a rapid decline in incidence 
rates occurred during 1995–1998 (–8.5% APC; 95% CI: –13.1%– –3.7%), with declines in 
subsequent years (2001–2013 (–4.4 APC; 95% CI: –4.7– –4.0)), followed by a slower 
decline during 2013–2017 (–1.6% APC; 95% CI: –3.4– 0.2) that was not statistically 
significantly different from a zero APC slope (Figure 2a). The trend in yearly TB case 
counts among non-US–born persons (Figure 2b), however, was substantially different from 
those of incidence rates. TB case counts among non-US–born persons were level during 
1993–2007 (0.2% APC; 95% CI: –0.1%– 0.4%), then declined during 2007–2012 (–4.5% 
APC; 95% CI: –6.3%– –2.7%), and were level again during 2013–2017 (0.5% APC; 95% 
CI: –0.9%–2.0%).
Similar to the overall TB incidence rates and case counts, US-born persons during 1993–
2017 (total 185 554 cases) experienced declining TB trends (Figure 3a and b). An incidence 
of 7.4/100,000 persons occurred in 1993, then declined at significant rates through 2013, 
(2006–2013 (–8.5 APC; 95% CI: –9.6– –7.4)). Thereafter, the incidence rate declined from 
1.2/100,000 in 2013 to 1.0/100,000 in 2017 (–5.3% APC; 95% CI: –7.9%– –2.6%). During 
2015, an increase of 149 TB cases was reported, compared with 2014 (142 cases among 
non-US–born persons, 7 cases among US-born persons), but the case count continued to 
decline significantly during 2013–2017 (Figure 3b).
Recent transmission estimates and TB confirmation
The estimated percentage of new TB cases attributed to recent transmission declined slightly 
during years for which these data were available (2011–2017). An average of 14.3% of TB 
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cases were attributed to recent transmission during 2011–2013, compared with 13.7% during 
2014–2017. Estimates of recent transmission among US-born persons was 26.5% for both 
time periods. Among non-US–born persons, an estimated 7.6% in 2011–2013 were 
attributed to recent transmission, compared with 8.1% during 2014–2017. Culture 
confirmation of TB infection is the reference standard for TB diagnosis and is necessary for 
genotyping analyses to estimate recent transmission. Since 2011, culture confirmation has 
remained constant at approximately 77% for all verified TB cases.1
Characteristics associated with recent epidemiology
Using multivariable regression, we analyzed characteristics of TB patients reported during 
2014–2017, compared with those reported during 2010–2013. Non-US–born TB patients in 
recent years were more likely to be older (≥45 years), nonwhite, have been in the United 
States <1 year or ≥10 years before TB diagnosis, or have diabetes (Table 1). Non-US–born 
TB patients in recent years were less likely to have cavitary disease at diagnosis, or have 
positive or unknown HIV status. Patients with other risk factors, such as, end-stage renal 
disease, contact with an infectious TB patient, or diagnosis with a non-HIV 
immunocompromising condition, did not differ statistically significantly when reported 
during the earlier or later time frame.
We analyzed the trends in case counts of non-US–born TB patients by the number of years 
since they had arrived in the United States before their TB diagnosis. Persons in the United 
States <1 year, 1–4 years, and ≥10 years after arrival had increasing TB case counts during 
during 2014–2017 (Table 2) compared to those in the United States during 2010 to 2013. 
Joinpoint analysis found those in the United States <1 year had no increase in case counts 
during 1993–2007 (0.15% APC; CI: –0.8%–1.1%), followed by a significant decline from 
2007 to 2011 (–12.0 APC; CI: –21.4%– –1.5%) and then were again level (3.1% APC; CI: –
1.2%– 7.5%) during 2011–2017. TB cases among those in the United States ≥10 years 
increased significantly throughout all years (1993–1998: 10.5% APC; CI: 8.9%– 12.1%; 
1998–2006: 2.3% APC; CI: 1.6%– 3.0%; 2006–2017: 0.96% APC; CI: 0.6%– 1.3%).
Among US-born TB patients, relative to whites, all racial/ethnic groups except non-Hispanic 
blacks were significantly more likely to be reported during 2014–2017, compared with 
2010–2013 (Table 2). US-born TB patients reported in 2014–2017, were more likely to be 
≥65 years of age, have combined pulmonary and extrapulmonary disease, have a positive 
sputum smear result at diagnosis, and report noninjecting drug use during the year before 
diagnosis. Among US-born TB patients, HIV infection, unknown HIV status, cavitary TB 
disease, excess alcohol use, and living in a correctional institution were less likely to be 
reported during 2014–2017, compared with 2010–2013.
Discussion
The slowing decline in the TB incidence rate was widespread during 2014–2017 across age, 
racial/ethnic, and geographic groups. No patterns were identified for changes in case 
verification by culture or recent transmission to account for the slowing decline.
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Through multiple analyses, we describe the recent epidemiology of TB in the United States 
that might have contributed to the slowing incidence rate declines. Compared with 2010–
2013, both US-born and non-US–born TB patients were more likely to be nonwhite, be 
older, and have less cavitary disease at TB diagnosis during 2014–2017. Older age at TB 
diagnosis is consistent with a US population that is growing at a faster rate among those 
aged ≥45 years than younger age groups.12 Along with older age, nonwhite minority racial/
ethnic groups were more likely to receive a TB diagnosis in recent years among both non-
US–born and US-born persons. Since race/ethnicity information regarding “whites” and 
“other races” was first collected in 1970,13 TB rates in the United States have been higher 
among nonwhite racial/ethnic groups and a recent report, showed all nonwhite racial/ethnic 
groups were approximately 3–54 times higher than for US-born whites.14
Other findings that may contribute to the slowing incidence of TB rates in recent years are 
that US-born TB patients were less likely to report excess alcohol use or to reside in a 
correctional institution at the time of diagnosis. Both US-born and non-US–born TB patients 
were more likely have been tested for HIV infection and have negative results. This is 
encouraging news for TB programs; HIV-testing in TB case management has been a 
longstanding goal for reaching elimination as have targeting TB in other marginalized 
populations, such as those in correctional institutions and homelessness. 3,15,16 Social 
determinants of health in the United States have long been linked to health disparities for 
nonwhite racial/ethnic groups.17 Our findings also indicate that noninjecting-drug use is 
increasing in recent years among the US-born. Thus, in spite of the good news, work 
remains to reduce TB in marginalized populations. Without screening for TB risk and 
treatment of latent TB infection among persons with prior exposures to TB, socioeconomic 
determinants and an aging population are likely to remain factors for increased risk for TB 
in the United States for future years.
Non-US–born TB patients reported during 2014–2017 were of older age and more likely to 
have been in the United States ≥10 years or <1 year before their TB diagnosis and have 
diabetes, compared with persons reported in prior years. A 2016 report18 noted that the 
smallest percentage decline in case counts during 2007–2011 occurred among non-US–born 
persons with TB who arrived in the United States ≥6 years before their TB diagnosis, and 
that epidemiologic patterns varied by country of birth and immigration. Another recent 
report highlighted the increased proportion of cases among non-US–born persons arriving in 
the United States ≥10 years before their TB diagnosis.19 TB cases among non-US–born 
persons who arrived in the United States ≥10 years before their diagnosis have increased 
during the last 2 decades which is consistent with immigration trends to the United States. 
The number of persons entering the United States from Mexico, China, India, Vietnam, and 
the Philippines has increased steadily for decades. Among these countries, only immigration 
from Mexico has declined slightly since 2010, after a rapid increase in immigration during 
previous decades.20
Diabetes among persons with latent TB infection is associated with increased progression to 
active disease21 and a delay in diagnosis of TB.22 Rates of diabetes among Hispanics, 
blacks,23 Pacific Islanders, 24 and certain Asian groups25 are substantially higher than rates 
for whites in the United States. Diabetes and TB comorbidity was independently associated 
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with TB cases reported during 2014–2017 among non-US–born but not US-born patients. 
This finding was expected, given that the percentage of diabetics among non-US–born TB 
patients has increased during 2010–2017, along with the increase in TB cases reported 
among older age groups. In contrast, among US-born persons, the percentage of diabetics 
and the number of cases among the older age groups has remained stable.
Conclusions
The slowing of the decline in TB rates demonstrated in this report emphasizes the concern 
that the aging of the US population and other factors (e.g. homelessness, 
immunosuppression caused by chronic medical conditions or medications, and progression 
to TB disease among persons infected with TB earlier in life) are likely to affect TB 
incidence for coming decades. To avert these trends, CDC has called for increased attention 
toward preventing TB through detection and treatment of latent TB infection among groups 
at high risk, including a call for standardized case-based surveillance of latent TB infection 
and expanded testing of these groups.26, 27
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Trends in tuberculosis incidence, US National Tuberculosis Surveillance System, 1993–
2017.
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Tuberculosis case counts, US National Tuberculosis Surveillance System, 1993–2017
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Incidence trends among non-US–born tuberculosis patients, US National Tuberculosis 
Surveillance System, 1993–2017.
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Trends in case counts among non-US–born tuberculosis patients, US National Tuberculosis 
Surveillance System, 1993–2017.
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Incidence trends among among US-born tuberculosis patients, US National Tuberculosis 
Surveillance System, 1993–2017.
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Trends in case counts among among US-born tuberculosis patients, US National 
Tuberculosis Surveillance System, 1993–2017.
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Tuberculosis case counts among non-US–born persons by time since arrival in the United 
States, US National Tuberculosis Surveillance System, 1993–2017.
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Table 1.
Demographic and Clinical Characteristics of Non-US–Born Tuberculosis Patients by Period, US National 











0–4 152 (0.6) 127 (0.5) 1.0 (0.8–1.2) .92
5–14 363 (1.4) 277 (1.1) 0.9 (0.8–1.0) .11
15–24 2878 (11.1) 2570 (10.1) 1.0 (1.0–1.0) .72
25–44 9842 (38.1) 8721 (34.3) Ref.
45–64 7217 (27.9) 7464 (29.4) 1.1 (1.0–1.1) <.0001
≥65 5403 (20.9) 6245 (24.6) 1.2 (1.1–1.2) <.0001
Race/Ethnicity
White, non-Hispanic 1283 (5.0) 1092 (4.3) Ref.
Asian, non-Hispanic 11919 (46.1) 12266 (48.3) 1.1 (1.1–1.2) <.0001
Black, non-Hispanic 3488 (13.5) 3498 (13.8) 1.1 (1.0–1.2) .0002
Hispanic 8783 (34.0) 8088 (31.8) 1.1 (1.0–1.1) .15
Other, non-Hispanicb 383 (1.5) 466 (1.9) 1.2 (1.1–1.3) <.0001
Years in the United States before tuberculosis diagnosis
<1 year 3958 (15.3) 4239 (16.7) 1.1 (1.1–1.2) <.0001
1–4 years 4514 (17.5) 4019 (15.8) 1.0 (1.0–1.1) .009
5–9 years 3851 (14.9) 3179 (12.5) Ref.
≥10 years 11194 (43.3) 11644 (45.8) 1.1 (1.1–1.1) <.0001
Unknown 2339 (9.1) 2329 (9.2) 1.1 (1.1–1.2) <.0001
HIV status (referent = HIV status negative)
Positive 1201 (4.6) 1075 (4.2) 0.9 (0.9–1.0) .0007
Unknownc 4824 (18.7) 2628 (10.3) 0.6 (0.6–0.7) <.0001
Site of Disease (referent = Extra-pulmonary disease only)
Pulmonary disease only 17159 (66.4) 17022 (67.0) 1.0 (1.0–1.1) .01
Pulmonary and extra-pulmonary disease 2662 (10.3) 2750 (10.8) 1.1 (1.0–1.1) .005
Chest radiology (referent = Normal chest radiograph)
Cavitary disease 4743 (18.3) 4484 (17.7) 0.9 (0.9–1.0) <.0001
No cavitary disease 15306 (59.2) 15124 (59.5) 1.0 (0.9–1.0) .01
Other Risk Factors
Diabetesd (referent = diabetes no or unknown) 4408 (17.1) 5340 (21.0) 1.1 (1.1–1.1) <.0001
AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus.
aAdjusted risk ratio and 99% confidence intervals shown for patient characteristics left in the final multivariable model. Variables were adjusted for 
sex; homelessness, excess alcohol use, injecting-drug use or non-injecting drug use within the year prior to diagnosis; living in a longterm care or a 
correctional facility at the time of diagnosis of TB; end-stage renal disease, previous history of TB, sputum smear results, history of incomplete 
treatment with tumor necrosis factor-alpha antagonist drugs, contact with an MDR TB patient, being missed contact of a person with TB disease, 
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post-organ transplantation, immunosuppression not associated with HIV/AIDS, treatment for latent tuberculosis infection, contact with an 
infectious TB or a multidrug-resistant TB patient, missed contact with active TB patient.
b
“Other” race/ethnicity includes persons of unknown or missing race (2010–2013, n = 62, 2014–2017, n = 75), more than one race selected (2010–
2013, n = 120; 2014–2017, n = 164), and Native Americans/Alaskan Natives (2010–2013, n = 7, 2014–2017, n = 4), and Native Hawaiians/Pacific 
Islanders (2010–2013, n = 194; 2014–2017, n = 223).
c
HIV, Human immunodeficiency virus status unknown is a combination of test result unknown, test refused, test not done, test not offered, and test 
result indeterminate.
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Table 2.
Demographic and Clinical Characteristics of US–Born Tuberculosis Patients by Period, US National 











0–4 1119 (7.4) 832 (7.0) 0.98 (0.9–1.1) .53
5–14 549 (3.6) 477 (4.0) 1.1 (1.0–1.2) .05
15–24 1334 (8.9) 1110 (9.4) 0.98 (0.9–1.0) .38
25–44 3244 (21.3) 2539 (21.4) Ref.
45–64 5545 (36.4) 4106 (34.6) 1.0 (1.0–1.1) .30
≥65 3426 (22.5) 2792 (23.5) 1.1 (1.0–1.2) <.0001
Race/Ethnicity
White, non-Hispanic 5088 (33.4) 3667 (30.9) Ref.
Asian, non-Hispanic 535 (3.5) 560 (4.7) 1.3 (1.2–1.4) <.0001
Black, non-Hispanic 5905 (38.8) 4399 (37.1) 1.0 (1.0–1.1) .29
Hispanic 2917 (19.2) 2507 (21.1) 1.1 (1.1–1.2) <.0001
American Indian/Alaskan Native, non-Hispanic 536 (3.5) 462 (3.9) 1.1 (1.0–1.2) .003
Native Hawaiian/Pacific Islander, non-Hispanic 110 (0.7) 158 (1.3) 1.5 (1.3–1.7) <.0001
Other, non-Hispanicb 126 (0.8) 106 (0.9) 1.1 (0.9–1.3) .21
HIV status (referent = HIV status negative)
Positive 1271 (8.4) 804 (6.8) 0.8 (0.8–0.9) <.0001
Unknownc 3039 (20.0) 1530 (12.9) 0.7 (0.6–0.7) <.0001
Site of disease (referent = extra-pulmonary disease)
Pulmonary disease only 11267 (74.0) 8748 (73.8) 1.0 (1.0–1.1) .036
Pulmonary and extra-pulmonary disease 1318 (8.7) 1121 (9.5) 1.1 (1.0–1.2) .005
Chest radiology (referent = normal chest radiograph)
Cavitary disease 3561 (23.4) 2719 (22.9) 0.9 (0.9–1.0) .005
No cavitary disease 8793 (57.8) 6867 (57.9) 1.0 (0.9–1.0) .08
Sputum smear results (referent = smear negative)
Positive 5585 (36.7) 4516 (38.1) 1.1 (1.0–1.1) .002
Unknown 3274 (21.5) 2573 (21.7) 1.1 (1.0–1.2) <.0001
Other Risk Factors (referent = not having risk factor)
Residing in a correctional institution 743 (4.9) 515 (4.3) 0.8 (0.7–0.9) <.0001
Excess alcohol use 3067(20.2) 2089 (17.6) 0.9 (0.8–0.9) <.0001
Noninjecting-drug use 2158 (14.2) 1846 (15.6) 1.2 (1.1–1.2) <.0001
AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus.
aAdjusted risk ratio and 99% confidence intervals shown for patient characteristics left in the final multivariable model. Variables were adjusted for 
sex; homelessness, injecting-drug use within the year prior to diagnosis; living in a longterm care facility at the time of diagnosis of TB; diabetes, 
end-stage renal disease, previous history of TB, history of incomplete treatment with tumor necrosis factor-alpha antagonist drugs, contact with an 
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MDR TB patient, being missed contact of a person with TB disease, post-organ transplantation, immunosuppression not associated with HIV/
AIDS, treatment for latent tuberculosis infection, contact with an infectious TB or a multidrug-resistant TB patient, missed contact with active TB 
patient.
b
“Other” race/ethnicity includes persons of unknown or missing race (2010–2013, n = 42, 2014–2017, n = 12) and more than one race selected 
(2010–2013, n = 84; 2014–2017, n = 94).
c
HIV, Human immunodeficiency virus status unknown is a combination of test result unknown, test refused, test not done, test not offered, and test 
result indeterminate.
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